There was some good news yesterday for individuals determined to be "at risk" for Multiple Sclerosis (MS). A groundbreaking new study published in the New England Journal of Medicine has demonstrated that early drug treatment can significantly delay the onset of multiple sclerosis (MS). The study's authors believe the research could result in a fundamental change in treatment for MS.
Avonex is an interferon. Interferons are a family of naturally occurring proteins and glycoproteins that are produced by eukaryotic cells in response to viral infection and other biological inducers. There's more information to be found in today's Vidyya. We have prescribing information, complete with instructions for safe, self-injection.
In drug approval news, the FDA has given the green-light to a new glue for used during a rare form of brain surgery. The glue offers an alternative to polyvinyl alcohol in patients at risk of hemorrhaging and dying from cerebral arteriovenous malformations (AVMs). The glue works by reducing blood loss by blocking blood vessels in the brain before surgery.
In device approval news, OSI Systems, Inc. announced that its Osteometer
MediTech subsidiary has received Pre-Market Approval (PMA) from the
FDA to market its UltraSure DTU-one ultrasound scanner in the United States. Although there are currently non-imaging ultrasound systems available in the
United States marketplace, this product marks the first PMA granted
for an imaging ultrasound system for assessment of osteoporotic
Rift Valley fever continues to spread throughout the Middle East. The Yemen Ministry of Health has reported 113 human cases, including 30 deaths of suspected Rift Valley fever in Wadi Mawr, Al-Hudaydah Governorate in northern Yemen. 266 animal deaths have also been reported, mainly of sheep and goats but some cattle and camels have been affected. The first case occurred on 10 September.
The articles in today's Vidyya are:
As always, we hope you enjoy the issue.